Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài: " Azithromycin in the extremely low birth weight infant for the prevention of Bronchopulmonary Dysplasia: a pilot study. | Respiratory Research BioMed Central Research Azithromycin in the extremely low birth weight infant for the prevention of Bronchopulmonary Dysplasia a pilot study Hubert O Ballard Michael I Anstead and Lori A Shook Open Access Address Pediatrics University of Kentucky 800 Rose Street Lexington KY40536 USA Email Hubert O Ballard - hoball2@ Michael I Anstead - Lori A Shook - lshook@ Corresponding author Published 5 June 2007 Received 15 February 2007 Respiratory Research 2007 8 41 doi l465-992l-8-41 Accepted 5 June 2007 This article is available from http content 8 l 4l 2007 Ballard et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Azithromycin reduces the severity of illness in patients with inflammatory lung disease such as cystic fibrosis and diffuse panbronchiolitis. Bronchopulmonary dysplasia BPD is a pulmonary disorder which causes significant morbidity and mortality in premature infants. BPD is pathologically characterized by inflammation fibrosis and impaired alveolar development. The purpose of this study was to obtain pilot data on the effectiveness and safety of prophylactic azithromycin in reducing the incidence and severity of BPD in an extremely low birth weight 1000 grams population. Methods Infants 1000 g birth weight admitted to the University of Kentucky Neonatal Intensive Care Unit level III regional referral center from 9 1 02-6 30 03 were eligible for this pilot study. The pilot study was double-blinded randomized and placebo-controlled. Infants were randomized to treatment or placebo within 12 hours of beginning mechanical ventilation IMV and within 72 hours of birth. The treatment group received azithromycin 10 mg
